PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
The investigators believe that the pharmacological properties of Envarsus®, well studied in
kidney transplantation, may be also suitable after simultaneous kidney and pancreas
transplantation than Prograf. Indeed, Envarsus® has demonstrated a clinical efficacy and
safety in a complete clinical development plan.
This study is to establish the pharmacokinetic profile of tacrolimus prolonged-release
(hereafter referred to as 'ENVARSUS®') in diabetics who have undergone kidney and pancreas
transplantation, and compare it to the pharmacokinetic profile of standard twice-daily
tacrolimus. The study will be conducted in 25 patients hospitalized at Nantes University
Hospital.